# Opgaver

## Prøveindsamling

### 2 projekter: 

**T/N seq af LSA, OSA og MT**
~40 prøver/år.
Mangler consent forms.

- N: Serum EDTA rør
- T: Biopsi eller cytologi

**Longitudinelt MT**
Skal defineres mere præcist.
10-20 med maligne MT (uanset oprindelse). Evt. benigne, men forløbslængde er sandsynligvis for langt i praksis.

For at øge sandsynligheden for at få brugbare resultater bør udvælgelse være T: ≥2 (tror det bliver svært at få nok med T≥3)

0-prøve med undersøgelse for cfDNA, hvis negativ, ikke videre undersøgelser (fordi hvis det ikke er der mens tumoren er der, så er der næppe noget efter den er fjernet, andet end måske lige umiddelbart efter)

- N: Liquid biopsy
- T: Biopsi eller cytologi+liquid biopsy fremadrettet.

***Inklusionskriterier***

- MT T:≥2,N:?,M:?
- Ikke dyrlægeskræk
- Ingen svær bivirkning ved anæstesi
- 0-prøve cfDNA positiv

## Dataanalyser

Flere mulige datasæt.

#### T/N data fra liquid biopsies

### WGS flatcoated retrievers

- Identificering af germ-line risikogener
- 18 hunde, allerede sekvenserede
- Kan med fordel bruges som data-øvesæt

**Plan**

- Lav filer klar til analyse
- Errent calls
- Find afvigelser fra referencegenom (flere hunde af forskellige racer)
- Sammenlign med andre modeller for histiocytær sygdomme

## Laboratorie forsøg i Uppsala

Kan enten være egen publikation eller i forbindelse med Majas overordnede projekt.
Benytter overskuds-DNA fra tidligere projekter. Issue med mulig kontamination fra normale celler.
Gerne finde tegn på duplikation af gener før lab-forsøg startes

HER2 copy nr. variants.
Design af assay

- - Primer design
    - Sammenlign med humane primers
  - Digital PCR
- Sammenlign HER2 copy nr antal med ref-gen som forventes at være singlecopy.

# TODO

- Tjek opbevaring af cfDNA (og noncfDNA)

# Random noter

The many similarities between various cancer types affecting humans and dogs and the spontaneous development of these cancers in immune competent canine individuals living in a shared environment with us suggest a common aetiology. The shorter lifespan of dogs and the shorter time to relapse after cancer treatment allows data regarding efficacy, short and long term toxicity and side effects of novel cancer drugs to be generated in years rather than decades as in human clinical trials.

However, certain limitations need to be overcome to make full use of the dog model. Slightly different classification systems for common cancers limit translation of data and clinical outcome from dog to human. The canine genome and annotation, especially that of complex immune gene families, could be improved to allow a more careful and correct comparison with the human genome and immune response, a key factor in cancer development and treatment.

We will specifically focus on canine mammary tumors, lymphoma and osteosarcoma where improved models would benefit human studies, and the canine forms are diverse and only partly characterized. Since the molecular sub-classifications used in human cancers are not yet used for these canine cancers, we plan to characterize these tumor types in the dog population using several approaches to meet human standards. We will perform repeated blood sampling from dogs with malignant mammary tumors to allow the study of tumor evolution and progression. All of this work will lay the groundwork to enable more useful and efficient future clinical trials.

This research aims to create a better genome assembly and gene and variant annotation, as well as a molecular comparison of canine mammary tumors, lymphoma and osteosarcoma to the human counterparts.